Production Method 1

84687-43-4

84676-88-0

86764-11-6

84676-89-1

84680-75-1

Reaction Conditions

1.1 Solvents: Water ;  48 h, rt

Reference

Microbial transformation of astragalosides to astragaloside IV by Absidia corymbifera AS2

Ye, Li; et al, Process Biochemistry (Amsterdam, 2011, 46(9), 1724-1730

Isoastragaloside I Raw materials

• Astragaloside IV

Isoastragaloside I Preparation Products

• Isoastragaloside II (86764-11-6)
• Isoastragaloside I (84676-88-0)
• Astragaloside II (84676-89-1)
• Astragaloside I (84680-75-1)

• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Cucurbitacin glycosides
• Triterpenoids
• Other Chemical Reagents

Isoastragaloside I (CAS No. 84676-88-0): A Comprehensive Overview

Isoastragaloside I (CAS No. 84676-88-0) is a bioactive saponin compound derived from the roots of Astragalus membranaceus, a traditional Chinese medicinal herb commonly known as Huang Qi. This compound has garnered significant attention in recent years due to its diverse pharmacological properties, including immunomodulatory, anti-inflammatory, and antioxidant activities. This comprehensive overview aims to provide an in-depth understanding of Isoastragaloside I, its chemical structure, biological activities, and potential therapeutic applications.

Chemical Structure and Properties

Isoastragaloside I is a triterpenoid saponin with the molecular formula C₄₁H₆₈O₁₄. Its molecular weight is approximately 784.97 g/mol. The compound features a complex structure with multiple hydroxyl groups and a sugar moiety, which contributes to its bioactivity. The presence of these functional groups allows Isoastragaloside I to interact with various biological targets, making it a versatile compound in medicinal chemistry.

Biological Activities and Mechanisms of Action

Isoastragaloside I has been extensively studied for its immunomodulatory effects. Research has shown that it can enhance the immune response by stimulating the production of cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ). These cytokines play crucial roles in the activation and proliferation of T-cells, thereby strengthening the immune system's ability to combat infections and diseases.

In addition to its immunomodulatory properties, Isoastragaloside I exhibits potent anti-inflammatory effects. Studies have demonstrated that it can inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). This inhibition helps to reduce inflammation and oxidative stress, which are key factors in the development of various chronic diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders.

The antioxidant activity of Isoastragaloside I is another important aspect of its biological profile. It has been shown to scavenge free radicals and reduce oxidative damage to cells and tissues. This property makes it a promising candidate for the prevention and treatment of oxidative stress-related conditions.

Clinical Applications and Therapeutic Potential

The diverse biological activities of Isoastragaloside I have led to its exploration in various clinical settings. One of the most promising areas of research is its potential use in enhancing immune function in patients with immunodeficiency disorders or undergoing chemotherapy. Clinical trials have shown that supplementation with Astragalus membranaceus extracts containing high levels of Isoastragaloside I can improve immune responses and reduce the incidence of infections in these patients.

In the context of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, Isoastragaloside I has shown potential as an adjunct therapy. Its ability to modulate inflammatory pathways may help to alleviate symptoms and improve quality of life for patients suffering from these conditions.

The antioxidant properties of Isoastragaloside I also make it a candidate for use in preventing age-related diseases. Preclinical studies have demonstrated that it can protect against oxidative damage in neuronal cells, suggesting its potential role in the prevention and treatment of neurodegenerative disorders like Alzheimer's disease.

Current Research Trends and Future Directions

Ongoing research is focused on elucidating the molecular mechanisms underlying the biological activities of Isoastragaloside I. Advances in genomics and proteomics are providing new insights into how this compound interacts with cellular signaling pathways. For example, recent studies have identified specific targets such as nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs) that are modulated by Isoastragaloside I.

In addition to basic research, there is growing interest in developing novel formulations of Astragalus membranaceus extracts enriched with Isoastragaloside I. These formulations aim to enhance bioavailability and therapeutic efficacy while minimizing side effects. Clinical trials are underway to evaluate the safety and effectiveness of these formulations in various patient populations.

Conclusion

Isoastragaloside I (CAS No. 84676-88-0) strong> is a multifaceted compound with significant potential for therapeutic applications. Its immunomodulatory, anti-inflammatory, and antioxidant properties make it a valuable candidate for treating a wide range of diseases. Ongoing research continues to uncover new mechanisms of action and potential clinical uses, paving the way for future developments in drug discovery and personalized medicine.

• 84687-47-8(Acetylastragaloside I)
• 223924-10-5(b-D-Glucopyranoside, (3b,6a,16b,20R,24S)-16-(acetyloxy)-20,24-epoxy-25-hydroxy-3-(b-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl(9CI))
• 101843-88-3(b-D-Xylopyranoside, (3b,6a,16b,20R,24S)-3-[(2-O-acetyl-b-D-xylopyranosyl)oxy]-20,24-epoxy-16,25-dihydroxy-9,19-cyclolanostan-6-yl)
• 86764-11-6(Isoastragaloside II)
• 88192-84-1(b-D-Xylopyranoside, (3b,6a,16b,24R)-20,24-epoxy-16,25-dihydroxy-6-(b-D-xylopyranosyloxy)-9,19-cyclolanostan-3-yl 2-O-a-L-arabinopyranosyl-, 3-acetate)
• 101843-89-4(β-D-Xylopyranoside, (3β,6α,16β,20R,24S)-3-[(3-O-acetyl-β-D-xylopyranosyl)oxy]-20,24-epoxy-16,25-dihydroxy-9,19-cyclolanostan-6-yl)
• 84676-89-1(Astragaloside II)
• 84680-75-1(Astragaloside I)
• 101843-86-1(b-D-Xylopyranoside, (3b,6a,16b,20R,24S)-20,24-epoxy-16,25-dihydroxy-6-(b-D-xylopyranosyloxy)-9,19-cyclolanostan-3-yl2-O-(6-deoxy-a-L-mannopyranosyl)-,4-acetate (9CI))
• 164991-87-1(β-D-Glucopyranoside, (3β,6α,16β,20R,24S)-3-[(2-O-acetyl-β-D-xylopyranosyl)oxy]-20,24-epoxy-16-hydroxy-9,19-cyclolanostane-6,25-diyl bis-)